At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CELZ Creative Medical Technology Holdings, Inc.
Market Closed 07-10 16:00:00 EDT
0.9121
-0.0292
-3.10%
盘后0.8811
-0.0310-3.40%
19:52 EDT
High0.9217Low0.8520Vol351.22K
Open0.9100D1 Closing0.9413Amplitude7.40%
Mkt Cap3.37MTradable Cap3.34MTotal Shares3.70M
T/O312.26KT/O Rate9.59%Tradable Shares3.66M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Creative Medical Technology Holdings Issues Mid-year Update
THOMSON REUTERS  ·  07-01
Creative Medical Technology Holdings Issues Mid-year Update
Creative Medical Technology Holdings Issues Mid-Year Update
GlobeNewswire  ·  07-01
Creative Medical Technology Holdings Issues Mid-Year Update
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds
THOMSON REUTERS  ·  07-01
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds
Top Premarket Decliners
MT Newswires Live  ·  06-26
Top Premarket Decliners
Creative Medical Files for Securities Offering
MT Newswires Live  ·  06-26
Creative Medical Files for Securities Offering
Creative Medical files to sell 3.05M shares of common stock
TIPRANKS  ·  06-26
Creative Medical files to sell 3.05M shares of common stock
Creative Medical expands ADAPT trial under new FDA clearance
TIPRANKS  ·  06-22
Creative Medical expands ADAPT trial under new FDA clearance
Creative Medical wins FDA clearance to expand ADAPT trial of Olastrocel in chronic lower back pain
Reuters  ·  06-22
Creative Medical wins FDA clearance to expand ADAPT trial of Olastrocel in chronic lower back pain
Creative Medical Technology Holdings Expands Adapt Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
THOMSON REUTERS  ·  06-22
Creative Medical Technology Holdings Expands Adapt Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
GlobeNewswire  ·  06-22
Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
Creative Medical advances Project PHOENIX burn pit exposure registry into nationwide AI-driven virtual data collection phase
Reuters  ·  06-16
Creative Medical advances Project PHOENIX burn pit exposure registry into nationwide AI-driven virtual data collection phase
Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards
GlobeNewswire  ·  06-16
Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards
Creative Medical Tech Q1 EPS $(0.38) Beats $(0.39) Estimate
Benzinga  ·  05-09
Creative Medical Tech Q1 EPS $(0.38) Beats $(0.39) Estimate
Creative Medical Technology Holdings Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-09
Creative Medical Technology Holdings Inc reports results for the quarter ended March 31 - Earnings Summary
Creative Medical net loss narrows 14.31% to $1.4 million in Q1 FY26
Reuters  ·  05-09
Creative Medical net loss narrows 14.31% to $1.4 million in Q1 FY26
Creative Medical Technology Holdings Inc expected to post a loss of 39 cents a share - Earnings Preview
Reuters  ·  05-06
Creative Medical Technology Holdings Inc expected to post a loss of 39 cents a share - Earnings Preview
Creative Medical knee data ‘highly positive,’ says Roth Capital
TIPRANKS  ·  04-28
Creative Medical knee data ‘highly positive,’ says Roth Capital
Creative Medical reports pilot study of Ultrasome meets priamry endpoint
TIPRANKS  ·  04-28
Creative Medical reports pilot study of Ultrasome meets priamry endpoint
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
GlobeNewswire  ·  04-28
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
Creative Medical Technology FY 2025 net loss rises 9% to USD 6 million on revenue down 46% to USD 6,000
Reuters  ·  03-21
Creative Medical Technology FY 2025 net loss rises 9% to USD 6 million on revenue down 46% to USD 6,000

Introduction

Company Name.
Creative Medical Technology Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Issue price:
--